一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> RSC Advances >>article
RSC Advances

RSC Advances

IF: 3.9
Download PDF

Advancements in drug discovery: integrating CADD tools and drug repurposing for PD-1/PD-L1 axis inhibition

Published:23 January 2025 DOI: 10.1039/D4RA08245A PMID: 39867321
Patrícia S. Sobral, Tiago Carvalho, Shiva Izadi, Alexandra Castilho, Zélia Silva, Paula A. Videira and Florbela Pereira

Abstract

Despite significant strides in improving cancer survival rates, the global cancer burden remains substantial, with an anticipated rise in new cases. Immune checkpoints, key regulators of immune responses, play a crucial role in cancer evasion mechanisms. The discovery of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 has revolutionized cancer treatment, with monoclonal antibodies (mAbs) becoming widely prescribed. However, challenges with current mAb ICIs, such as limited oral bioavailability, adverse effects, and high costs, underscore the need to explore alternative small-molecule inhibitors. In this work, we aimed to identify new potential ICI among all FDA-approved drugs. We employed QSAR models to predict PD-1/PD-L1 inhibition, utilizing a diverse dataset of 29?197 molecules sourced from ChEMBL, PubChem, and recent literature. Machine learning techniques, including Random Forest, Support Vector Machine, and Convolutional Neural Network, were employed for benchmarking to assess model performance. Additionally, we undertook a drug repurposing strategy, leveraging the best in silico model for a virtual screening campaign involving 1576 off-patent approved drugs. Only two virtual screening hits were proposed based on the criteria established for this approach, including: (1) QSAR probability of being active against PD-L1; (2) QSAR applicability domain; (3) prediction of the affinity between the PD-L1 and ligands through molecular docking. One of the proposed hits was sonidegib, an anticancer drug, featuring a biphenyl system. Sonidegib was subsequently validated for in vitro PD-1/PD-L1 binding modulation using ELISA and flow cytometry. This integrated approach, which combines computer-aided drug design (CADD) tools, QSAR modelling, drug repurposing, and molecular docking, offers a pioneering strategy to expedite drug discovery for PD-1/PD-L1 axis inhibition. The findings underscore the potential to identify a wider range small molecules to contribute to the ongoing efforts to advancing cancer immunotherapy.

Similar articles

IF:56.7

Aprepitant: drug–drug interactions in perspective

Annals of Oncology M.S. Aapro , C.M. Walko,etc Published: 1 December 2010
IF:19.8

Generation of iPSC-derived human venous endothelial cells for the modeling of vascular malformations and drug discovery

Cell stem cell Zihang Pan, Qiyang Yao,etc Published: 22 November 2024
IF:4.3

Dendrimer-Encapsulated Pd Nanoparticles versus Palladium Acetate as Catalytic Precursors in the Stille Reaction in Water

Inorganic Chemistry María Bernechea, Ernesto de Jesús*,etc Published: 7 April 2009
彰化市| 离岛区| 西青区| 太和县| 绥芬河市| 饶平县| 宁津县| 南汇区| 普格县| 华阴市| 湖北省| 湘潭县| 北宁市| 县级市| 盐源县| 聂拉木县| 临邑县| 甘泉县| 南郑县| 达尔| 南充市| 太康县| 开江县| 南昌县| 常山县| 黑龙江省| 蒙城县| 建湖县| 潼关县| 郯城县| 洛阳市| 固镇县| 句容市| 永嘉县| 桐庐县| 神木县| 沐川县| 屏东市| 曲阜市| 丰原市| 阿巴嘎旗|